Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SYNERCID is a fixed-dose combination injectable antibiotic containing quinupristin and dalfopristin, streptogramin agents approved in 1999 by Pfizer. It is used to treat serious infections caused by Gram-positive bacteria, including vancomycin-resistant Enterococcus faecium (VREF) and other resistant pathogens. The dual components work synergistically to inhibit bacterial protein synthesis.
Product is in late-stage lifecycle with moderate competitive pressure (30/100); brand team likely focused on line-extension or positioning for generic transition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
SYNERCID offers limited entry-level or growth-focused career opportunities due to its LOE approaching lifecycle and narrow specialist indication. Roles are concentrated in hospital sales, payer management, and medical information for ID specialists, with emphasis on defending market share rather than expansion.
Worked on SYNERCID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.